ArticleMediators of inflammation2012
Erythromycin enhances CD4+Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation.
Article in Mediators of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- The Multifaceted Role ofGenes · 2025Review
- Gut-derived immune cells and the gut-lung axis in ARDS.Critical care (London, England) · 2024Review
- Indocyanine-enhanced mouse model of bleomycin-induced lung fibrosis with hallmarks of progressive emphysema.American journal of physiology. Lung cellular and molecular physiology · 2023Article
- Erythromycin: an alternative for the management of oral mucositis?Medicina oral, patologia oral y cirugia bucal · 2022Review
- Potential therapeutic effects of interleukin-35 on the differentiation of naïve T cells into HeliosMolecular immunology · 2021Article
- Article
- Erythromycin Suppresses the Cigarette Smoke Extract-Exposed Dendritic Cell-Mediated Polarization of CD4Journal of immunology research · 2020Article
- Rapamycin attenuates Tc1 and Tc17 cell responses in cigarette smoke-induced emphysema in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Article
- Insights into the immuno-pathogenesis of acute respiratory distress syndrome.Annals of translational medicine · 2019Review
- Erythromycin suppresses neutrophil extracellular traps in smoking-related chronic pulmonary inflammation.Cell death & disease · 2019Article
- Macrolides for treatment of chronic obstructive pulmonary disease.Chinese medical journal · 2019Article
- Interleukin-35 as an Emerging Player in Tumor Microenvironment.Journal of Cancer · 2019Review
- Erythromycin Prevents Elastin Peptide-Induced Emphysema and Modulates CD4International journal of chronic obstructive pulmonary disease · 2019Article
- Regulatory T Cells and Acute Lung Injury: Cytokines, Uncontrolled Inflammation, and Therapeutic Implications.Frontiers in immunology · 2018Review
- Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease.Therapeutic advances in respiratory disease · 2017Review
- Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent.Mediators of inflammation · 2017Review
- Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program.Journal of molecular neuroscience : MN · 2015Article
- Anti-inflammatory effects of potato extract on a rat model of cigarette smoke-induced chronic obstructive pulmonary disease.Food & nutrition research · 2015Article
- IL-35: a potential therapeutic target for controlling hepatitis B virus infection.Journal of digestive diseases · 2015Review
- Interleukin-12 family cytokines and sarcoidosis.Frontiers in pharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heavy smoking can induce airway inflammation and emphysema. Macrolides can modulate inflammation and effector T-cell response in the lungs. However, there is no information on whether erythromycin can modulate regulatory T-cell (Treg) response. This study is aimed at examining the impact of erythromycin on Treg response in the lungs in a rat model of smoking-induced emphysema. Male Wistar rats were exposed to normal air or cigarette smoking daily for 12 weeks and treated by gavage with 100 mg/kg of erythromycin or saline daily beginning at the forth week for nine weeks. The lung inflammation and the numbers of inflammatory infiltrates in bronchoalveolar lavage fluid (BALF) were characterized. The frequency, the number of Tregs, and the levels of Foxp3 expression in the lungs and IL-8, IL-35, and TNF-α in BALF were determined by flow cytometry, RT-PCR and ELISA, respectively. Treatment with erythromycin reduced smoking-induced inflammatory infiltrates, the levels of IL-8 and TNF-α in the BALF and lung damages but increased the numbers of CD4+Foxp3+ Tregs and the levels of Foxp3 transcription in the lungs, accompanied by increased levels of IL-35 in the BALF of rats. Our novel data indicated that erythromycin enhanced Treg responses, associated with the inhibition of smoking-induced inflammation in the lungs of rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.